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INTRODUCTION
Metronomic chemotherapy (regular administration of conventional chemotherapeutic drugs at low, minimally toxic doses, with no prolonged drug-free breaks) appears to fulfil many of the requirements of an optimal multitarget therapy (minimal toxicities to allow for combinations, targeting not only the tumour but also the tumour microenvironment, etc.) 1 .
Although the effectiveness and rationale of MTD-based chemotherapy regimens and doseescalation strategies have been questioned for many years, especially in patient populations with poor-prognosis tumours 2 , we have lacked sufficient convincing preclinical data to validate the potential of other alternative schedules of drug administration. Nevertheless, one such groundbreaking preclinical study was published ten years ago by Browder et al. 3 working in Judah Folkman's laboratory, the results being confirmed in Robert Kerbel's laboratory 4 . Using transplantable tumours 3 and xenograft models 4 , the two teams demonstrated that the frequent administration of low-dose chemotherapy could produce potent anticancer effects through the inhibition of angiogenesis.
In contrast to conventional MTD chemotherapy, the main primary target of metronomic chemotherapy is thought to be the tumour's neovasculature, although this is considered to be only an initial site of action, and additional mechanisms are probably involved 5 . Kerbel and Kamen 5 suggested that combining standard MTD chemotherapy with metronomic chemotherapy might have a synergistic effect. MTD chemotherapy would debulk the tumour before the initiation of metronomic chemotherapy, which would then have an antiangiogenic effect, while abolishing the endothelial cell rebound 6 . The concepts of combining metronomic chemotherapy with MTD chemotherapy or with agents targeting VEGF and PDGF receptors were brought together in a single preclinical study reported by
Pietras and Hanahan 7 .
In this article, we generalise this chemo-switch concept to other tumour models and other drugs, evaluating its effects on angiogenesis and cancer stem cell (CSC) number.
MATERIAL AND METHODS

Drugs
Gemcitabine and cyclophosphamide (CTX) were provided by the Pharmacological Department of our institution. Both were dissolved in buffered saline solution at the corresponding concentrations according to the different doses and schedules.
Gemcitabine was administered by intraperitoneal injection in all treatment schedules, while cyclophosphamide was administered intraperitoneally (i.p.) when given at the maximum tolerated dose and orally by gavage when following the metronomic low dose.
DC101, an anti-VEGFR2 blocking antibody, was purified from a hybridoma culture (American Type Culture Collection). It was administered twice a week i.p. to mice at a dose of 4 mg/mouse, as previously described 8 .
Orthotopic models
Three orthotopic tumour models were used in this study, all of which originated after implantation of fresh surgical tumour samples obtained from primary tumour patients. NP9
is a poorly differentiated tumour obtained from a human pancreatic peritoneal metastasis that had been perpetuated by orthotopic implantation in nude mice. It presents TP53 and KRAS point mutations, which are common in pancreatic cancers 9 . TP11 was generated from a pancreatic human tumour. It is a moderately differentiated adenocarcinoma that, in addition to TP53 and KRAS point mutations, presents a deletion of part of exon1 of CDK2N (p16) (Ginesta et al, manuscript in preparation). OVA17 is a serous ovarian carcinoma that was also directly generated by orthotopic implantation in mice of a human primary tumour (A. Villanueva et al, manuscript in preparation).
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Four-week-old male athymic nude mice weighing 18-22 g (Harlan Laboratories, France) were used for NP9 or TP11 human pancreatic tumour implantation and expansion.
Similarly, five-week-old female nu/nu Swiss mice (Harlan Laboratories) were used for the OVA17 ovarian tumour. Briefly, athymic mice were anaesthetised by isopropyl alcohol inhalation, and implantation was performed by sewing the tumour fragments to the pancreas or the ovaries with prolene 7.0 suture following an abdominal incision. Animals were housed in a sterile environment; cages, water, and bedding were autoclaved and food was γ-ray-sterilised. All protocols were approved by the local committee for animal care (IDIBELL).
Treatment schedules
In pancreatic tumour models, gemcitabine treatment started when the tumour volume reached roughly 0.5 to 1.0 cm 3 (palpable tumour volume) by 15 days post-implantation for NP9 and 4 weeks post-implantation for TP11. Once the tumour volume was palpable, mice (n=30) were randomised into four cohorts and distributed to control (n=7) and three different treatment groups, receiving the MTDG schedule (n=8), the METG schedule (n=8) or the C-SG schedule (n=7). The control group received sham injections daily with vehicle alone (saline serum). Treatment was 28 days long, reproducing one cycle of treatment.
Animals were weighed twice per week during treatment. At sacrifice, animals were bled from cardiac puncture and blood was collected for the study of haematological variables.
Tumours were excised, measured and processed for the various analyses.
For the maximum tolerated dose gemcitabine (MTDG) schedule, we chose 100 mg/kg delivered four times at 3-day intervals by intraperitoneal injection (days 0, 3, 6, and 9 every 28 days, where day 0 is counted as the day of palpable volume). We had previously shown significant effectiveness in dose-finding experiments at this dose, and this has been established as the MTDG in the literature 10, 11 . Nevertheless, when we continuously administered MTD during the entire cycle we found inacceptable toxicity in mice, so this option was discarded.
Animals treated with gemcitabine on the metronomic low-dose schedule (METG), received 1 mg/kg daily until sacrifice, as established by previous studies 11 .
Administration of the gemcitabine chemo-switch (C-SG) was performed combining both schedules: MTDG followed by METG until sacrifice (100 mg/kg on days 0, 3, 6 and 9, followed by 1 mg/kg daily from day 12 until day 28).
Finally, as a combination schedule of gemcitabine at the MTD followed by an antiangiogenic maintenance treatment, we performed an additional experiment: once NP9 tumours were palpable, 25 nu/nu mice were randomly distributed to a control (n=6) and three experimental treatment groups: METG (n=5), C-SG (n=7) and MTDG+DC101 (n=7).
In the latter group, animals received the MTDG schedule followed by antiangiogenic treatment until sacrifice (antibody DC101 at 4 mg/mouse twice a week from day 12 to day 28) 8 . As in the previous in vivo study, the treatment lasted 28 days, after which the animals were sacrificed; tumours were excised and processed as described above.
In the in vivo ovarian cancer experiment, OVA17 ovarian tumour fragments were implanted in female nude mice, one in each ovary. Once tumours were palpable (by day 50 post-implantation) animals were randomised to the cyclophosphamide chemo-switch treatment (C-S CTX) (n=5) and control (CTL) (n=5) groups. The C-S CTX treatment was performed by combining the MTD and metronomic cyclophosphamide doses and schedules, as described in previous studies 6, 12 , and adapting these protocols to OVA17 tumour growth behaviour. During the 28-day treatment cycle, animals in the CS CTX group received first 150 mg/kg (MTD) three times at 2-day intervals by intraperitoneal injection (days 0, 2, 4), followed by 20 mg/kg daily and orally by gavage (metronomic dose) from day 13 until sacrifice. CTL mice received saline serum i.p. or orally by gavage as required.
Peritoneal dissemination analysis by quantification of mesenteric nodes
After sacrifice, the mesenteric region of each mouse was excised and carefully exposed.
Photographs were taken of all samples. We used the Volocity Demo program (PerkingElmer Inc.) to count the absolute number of nodes in the mesentery of each mouse and to calculate the ratio of the tumour area relative to the total area of mesentery.
Immunofluorescence staining
Three-micrometer-thick OCT sections were cut and used for immunofluorescence staining analysis.
Proliferative activity was analysed by Ki67 (NeoMarker) staining. The tumour Ki67+ index was determined from counts of Ki67+ cellular nuclei relative to the total number of cells per field. We analysed four fields (40x) per tumour from five mice from each treatment and control group.
Blood vessel density was analysed by CD31 (BD PharMigen; endothelial marker) and laminin (Sigma Aldrich; basement membrane marker found surrounding blood vessels) double-staining. Tumour microvessels were analysed by measuring the relative area of CD31+ or laminin+, which was determined as the area of CD31-or laminin-stained vessels per measured field. We analysed four fields (20x) per tumour from four mice from each treatment and control group. Quantification was expressed in both cases as the positive relative area and was calculated using the Volocity Demo (PerkingElmer Inc) program.
Western blot
NP9 tumours were lysed in Laemmly sample buffer (63 mM Tris HCl, 2% SDS, 10% glycerol, pH 6.8). Insoluble material was removed by centrifugation at 11,000 rpm for 10 9 min at 4ºC. The protein concentration of the lysate was quantified by the Pearce BCA protein quantification method (Thermo Scientific). Equal amounts of protein were loaded and separated by SDS-polyacrylamide gels and transferred onto PVDF membranes. The membranes were blocked with 5% non-fat milk powder in TBS (150 mM NaCl, 50 mM Tris, pH 7.4) for 1 h and probed with primary antibodies against TSP-1 (NeoMarkers) or monoclonal anti-tubulin (Sigma Aldrich) overnight at 4ºC. After washing with TBS-0.1%
Tween, blots were incubated with anti-mouse IgG and revealed with the ECL system (GE Healthcare).
Quantitative densitometry was carried out using the Quantity One (BioRad Laboratories,
Flow cytometry analyses
Single-cell suspensions were prepared from NP9 tumours by mechanical and enzymatic dissociation. 
Statistical analysis
Statistical analyses were done with SPSS v.13.0 (SPSS, Inc., Chicago, IL Administration of gemcitabine following C-S produced the best anti-tumour response, reducing tumour growth by up to 80% (M=0.64 cm 3 ) (Fig. 1A ). This effect on tumour volume was correlated with a significantly lower expression of the proliferation marker Ki67 (Fig. 1B) .
Treatment following the chemo-switch schedule did not increase conventional treatment toxicity
During gemcitabine administration no significant differences in the mean weight of mice in the control, MTD, MET and C-S groups (Sup. Fig. 1A ). Moreover, to study the potential toxicity of the C-SG treatment, blood samples were collected on sacrifice day (day 28) to analyse haematological characteristics: segmented neutrophils, haematocrit and platelet count. There were no significant differences between the C-SG and the MTDG or METG groups, suggesting that the C-SG schedule did not increase toxicity relative to other treatments (Sup. respectively). Inhibition was 50% compared with the controls (M=2.4 cm 3 ), the difference being statistically significant (Fig 2A) . Combining the two treatments in the C-SG schedule, tumour growth was significantly lower than in all other groups (M=0.71 cm 3 ;
P=0.014 compared with CTL; P=0.047 compared with MTDG and METG).
Cyclophosphamide following the chemo-switch schedule blocked ovarian tumour growth
To determine whether the results obtained in pancreatic cancer models could be reproduced in a different cancer model, we studied the chemo-switch schedule in OVA17, an ovarian serous tumour model. Cyclophosphamide is the most widely explored agent for a metronomic approach in this type of tumour 13 . In OVA17, the cyclophosphamide C-S schedule had a dramatic effect (M=1.57 cm 3 ), inhibiting tumour growth by almost 90% compared with the control group (M=0.15 cm 3 ; P=0.014) (Fig 2B) , while not having a significant effect on mouse weight (Sup. Fig. 1C ).
NP9 tumour peritoneal dissemination was blocked by gemcitabine following the metronomic and chemo-switch schedules
Gemcitabine treatment schedules had an effect on tumour peritoneal dissemination that was macroscopically observed in mice mesenteries (Fig 3A) . CTL mice showed extensive macroscopic tumour peritoneal nodes, which were reduced to a few small, but visible, nodes in the MTDG group. In contrast, no dissemination was observed in the METG and C-SG groups.
To evaluate this effect, we counted the number of tumour nodes per mesentery (Fig 3B) and measured the relative tumour area per mesentery (Fig 3C) . Peritoneal analysis showed that mesenteric nodes were larger and more abundant in the CTL group than in the MTDG group. Macroscopic peritoneal dissemination was completely inhibited in the METG and C-SG groups.
Treatment with gemcitabine following the metronomic and chemo-switch schedules reduced blood vessel density in NP9 tumours and increased thrombospondin-1
We evaluated the effect of the different gemcitabine treatments on the angiogenic pattern of NP9 pancreatic tumours (Fig. 4A) . We found no significant differences in endothelial relative areas (CD31 and laminin staining) between the MTDG treatment and control groups. In contrast, in the METG and the C-SG groups, we found a similar and marked reduction of the endothelial area (Fig 4B and C) . These results suggest that a potential antiangiogenic mechanism of action was at least partially responsible for the effect of C-SG on tumour growth.
To confirm this possibility, we performed a new in vivo experiment in NP9 tumours to compare the C-SG regimen with a new combination group: mice receiving the MTD-G schedule followed by an antiangiogenic treatment based on administration of the antibody DC101 until sacrifice (MTDG+DC101). This enabled us to confirm previous anti-tumour growth results in the METG and C-SG treatment groups compared with the control (M=0.6 cm 3 , 0.18 cm 3 and 1.24 cm 3 respectively) (Fig. 5A) . The marked anti-tumour effect in the 13 C-SG group was significantly stronger than that produced by the metronomic regimen.
When we analysed the effect of MTDG+DC101 treatment (M=0.13 cm 3 ), we found tumour growth to be reduced by the same proportion as in C-SG: 80% compared with the control group.
Analysing tumour microvessel density in this second in vivo experiment showed that antiendothelial effect was quite similar in the METG and C-SG treatment groups and equivalent to the expected effect of the antiangiogenic MTDG+DC101 treatment group (Fig. 5B) .
Induction of the antiangiogenic factor thrombospondin-1 is one of the most important effects of the metronomic treatment. To establish whether the C-S schedule also affects thrombospondin-1 we measured protein levels by western blot. Metronomic and chemoswitch treatments induced thrombospondin-1 (x4 and x2.5 respectively, Fig. 5C ). In contrast, anti-VEGFR2 DC101 treatment did not induce this protein, confirming a completely different antiangiogenic mechanism mediated by VEGFR2 inhibition.
Gemcitabine following the metronomic and the chemo-switch schedules reduced cancer stem cells levels
Finally, given that the presence of cancer stem cells (CSCs) may contribute to tumour resistance to classical chemotherapy 14 , and the previously described effects of metronomic chemotherapy on circulating endothelial cell progenitors 5 , we decided to investigate whether metronomic and/or chemo-switch schedules could affect CSC populations in our NP9 pancreatic tumour model. To this end, after treatment, tumours were disaggregated and human cells analysed using flow cytometry with specific antibodies. We measured the surface expression of three antigens: CD133, CD44 and CD24. The amount of human CD133+, a general marker of progenitor cells, was not significantly modified by MTDG treatment (2.12% CD133+ cells in control group, 1.88% in MTDG group) (Fig. 6A) . In 14 contrast, the metronomic schedule caused a significant drop of 67% in CD133+ cells 
DISCUSSION
In the present study we sought to explore the anti-tumour efficacy of a metronomic gemcitabine schedule in two different orthotopic pancreatic cancer models (NP9 and TP11), both of which are characterised by aggressive cancer growth and, in the case of the NP9 model, by metastatic development. We aimed not only to reproduce our previous results 11 in these more aggressive models, but also and more importantly, to test a combinatorial chemo-switch schedule in which metronomic chemotherapy was given after conventional MTD treatment. In our pancreatic tumour models, this C-S schedule had the most favourable effect, yielding at least 80% of tumour growth inhibition but with no 
